Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 240 participants.

Also called NCT01464476

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 240 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01464476
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Canada, Czechia, Denmark, France, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01464476. Randomized; triple masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Acronym
SHIELD-2
Condition
Arrhythmias, Cardiac
Condition
Heart Diseases
Condition
Cardiovascular Diseases
Condition
Implantable Cardioverter Defibrillator
Intervention (Drug)
Azimilide Dihydrochloride
Intervention (Drug)
Placebo
Lead sponsor
Forest Laboratories (class: industry)

Record details

Record id
cardio:ct-nct01464476
Content hash
0eb57f241d0318b39f21b4d96f29e37f325af08d477c6df87e05f7bda79742a3